Investors can start buying shares in several leading artificial intelligence (AI) stocks with a modest sum of just $1,000.

Change isn’t slowing down — smart companies are learning to turn volatility into opportunities instead of obstacles.

A formulation of MSD's cancer drug Keytruda that can be given by subcutaneous injection rather than intravenous infusion has cleared a phase 3 trial, setting up approvals later this year. The ...

In 2024, North America held a dominan market position, capturing more than a 38.7% share, holding USD 1.3 Billion revenue.